Biodexa Pharmaceuticals plc key statistics and ratios

In fiscal 2023, Biodexa Pharmaceuticals plc had return on equity of -180.1%, an operating margin of -2103.4%, debt equal to 6.3% of equity and a current ratio of 1.26. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biodexa Pharmaceuticals plc: financial ratios, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Gross margin	94.9%	—	—	—	—	—	—	—	—
Operating margin	−939.5%	−729.6%	<−999%	−609.6%	<−999%	<−999%	<−999%	<−999%	<−999%
Net margin	−734.5%	<−999%	<−999%	−775.5%	<−999%	<−999%	−944.6%	<−999%	<−999%
Free-cash-flow margin	−970.4%	<−999%	<−999%	−706.6%	<−999%	<−999%	<−999%	<−999%	<−999%
Return on equity	−22.3%	−43.5%	−40.1%	−58.6%	−54.2%	−162.1%	−64.5%	−105.7%	−180.1%
Return on assets	−16.3%	−33.3%	−30.3%	−43.3%	−38.4%	−104.6%	−48.7%	−78.6%	−87.6%
Asset turnover	0.02	0.02	0.02	0.06	0.03	0.02	0.05	0.07	0.05
Current ratio	2.23	2.39	2.22	2.27	2.42	3.10	6.39	2.47	1.26
Debt to equity	3.2%	3.5%	17.8%	5.2%	29.0%	3.0%	5.9%	14.6%	6.3%
Interest cover (operating income ÷ interest)	—	—	—	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	633.5%	584.3%	842.2%	482.9%	>999%	>999%	805.2%	731.2%	>999%
Capital spending as % of revenue	67.1%	101.8%	71.5%	12.6%	46.0%	60.9%	55.4%	8.9%	6.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · December 31, 2025

What it owns · $24m

Short-term assets $17mLonger-term assets $8m

What it owes, and who funded it · $24m

Short-term liabilities $8mLonger-term liabilities $1mShareholders' equity $15m

Short-term assets cover short-term liabilities $17m of assets due within a year against $8m of liabilities due within a year.
Short-term assets cover long-term liabilities $17m short-term assets against $867,332 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$11m against $13,192 of interest.

From Biodexa Pharmaceuticals plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biodexa Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biodexa Pharmaceuticals plc.